NewsRoom Articles - Page 210 of 213

TuesdayApr 21, 2020 12:59 pm

Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved

Q4 highlights include $15 million equity line, CancerQuest 2020 initiative POAI revenues for FY 2019 total $1.4 million, primarily driven through sale of proprietary STREAMWAY units Predictive Oncology will continue to be pioneer in fields of biomarker discovery, precision therapies Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying its cutting-edge technology to cancer research, released its financial report for fiscal year 2019, ending December 31, 2019. The report also identified fourth-quarter highlights for the company (http://nnw.fm/5uhu6). Noting that 2019 “was not without its challenges for the entire healthcare technology industry,” POAI CFO Bob Myers observed that Predictive Oncology “continued…

ThursdayApr 09, 2020 12:29 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer

POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer. This achievement will be a key milestone for the company’s CancerQuest2020 initiative (http://nnw.fm/W2TJb). CancerQuest2020 is focused on building an…

ThursdayMar 26, 2020 12:42 pm

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million

POAI announces securities purchase agreement with accredited investors to purchase shares of common stock Company to use net proceeds from purchase agreement for general corporate purposes Agreement expected to raise $3.5 million through issuance of up to 1,650,165 shares of common stock or common stock equivalents Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock; the company plans to use the net proceeds from the purchase agreement for general corporate purposes. POAI, a company that focuses on providing predictive models of tumor drug…

ThursdayMar 19, 2020 12:25 pm

AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes

Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases Predictive Oncology launches new AI platform in fight against new pathogens Artificial intelligence likely to help find COVID-19 vaccines and therapeutics With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then…

TuesdayMar 17, 2020 12:10 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) AI Solutions to Combat Cancer, Similar Technological Solutions Called Upon to Fight COVID-19

Artificial intelligence (AI) at forefront of scientific discovery, proving importance in fighting complex diseases Science turns to AI as effective tool to help find COVID-19 vaccines and therapeutics Predictive Oncology harnesses power of AI to improve cancer patient outcomes With the global onslaught of COVID-19, scientists are harnessing the speed and power of artificial intelligence (AI) to find solutions. The complexity of this lethal contagion demands a rapid yet comprehensive response, and only advanced computer systems can parse through mountains of data sets swiftly enough to stem the pandemic. AI’s ability to sort and sift data quickly, spot patterns and…

FridayMar 13, 2020 11:30 am

Predictive Oncology Inc. (NASDAQ: POAI) AI/ML Expertise, Recent Acquisition Invaluable Resources in Search for New Anti-Virals, Vaccines

POAI positioned as leader in using data, artificial intelligence in search for novel effective treatments Planned acquisition provides Predictive Oncology with CoRE(TM), a proven machine-learning framework Uniting CoRE with proprietary PDx tumor-profiling platform and tumor-data database creates one-of-a-kind, end-to-end “discovery machine” With its recent proposed acquisition of Carnegie Mellon spin-out Quantitative Medicine, Predictive Oncology Inc. (NASDAQ: POAI), a leader in using data and artificial intelligence (AI) to develop personalized cancer therapies, demonstrates its strong position in assisting in the search for new anti-cancers, anti-virals, antibiotics and vaccines. POAI’s expertise in this area is particularly relevant in light of the current…

TuesdayMar 10, 2020 1:47 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member with Impressive CSO, Senior Research Background

Dan Handley brings wealth of invaluable experience to POAI’s board of directors Newest board member has extensive experience with entities closely associated with POAI’s Helomics division Predictive Oncology set to benefit from Handley’s broad knowledge, expertise Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, has announced the unanimous appointment of its newest board member (http://nnw.fm/TlGT0). Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s already impressive board of directors. “Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” POAI CEO Dr. Carl Schwartz stated…

ThursdayMar 05, 2020 11:05 am

Predictive Oncology Inc. (NASDAQ: POAI) Signs LOI for Acquisition of Leading Biomedical Analytics Company, Novel Drug-Discovery Platform

POAI’s planned acquisition of Quantitative Medicine (QM) will revolutionize the way precision therapies are developed QM’s CoRE platform predicts main effects of drugs on target molecules that mediate disease Synergies created by acquisition support POAI’s efforts to accelerate the commercialization of its AI-driven predictive model services Predictive Oncology Inc. (NASDAQ: POAI) has announced the latest development in its mission to become the leader in the cancer precision-medicine field. In line with its focus on applying artificial intelligence (AI) to personalized medicine and drug discovery, POAI has signed a signed a Letter of Intent to acquire Quantitative Medicine (QM), a leading…

WednesdayMar 04, 2020 11:27 am

Predictive Oncology Inc.’s (NASDAQ: POAI) Key Focus Areas of Precision Medicine, AI Listed as Top Industry Investment Trends

Precision medicine, AI among top healthcare investment trends for 2020 Predictive Oncology is data, AI-driven precision medicine company with an exclusive database of patient samples Market estimates for precision medicine expected to reach $84.6 billion by 2024 Precision medicine and artificial intelligence rank high on the list of top investment-focused healthcare trends, according to a recent Emagine article (http://nnw.fm/jKVt0). Both are key areas of focus for Predictive Oncology Inc. (NASDAQ: POAI), a leading data and artificial-intelligence-driven precision medicine company. In an arena where data is king and artificial intelligence is increasingly gravitating to the spotlight, POAI is uniquely positioned with…

MondayFeb 24, 2020 12:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

POAI subsidiary announces new media for growing ovarian tumors in lab Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers New media available as cell-culture market expected to reach $2.3 billion by 2024 Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://nnw.fm/2bdtl). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million

AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes

Predictive Oncology Inc.’s (NASDAQ: POAI) AI Solutions to Combat Cancer, Similar Technological Solutions Called Upon to Fight COVID-19

Predictive Oncology Inc. (NASDAQ: POAI) AI/ML Expertise, Recent Acquisition Invaluable Resources in Search for New Anti-Virals, Vaccines

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member with Impressive CSO, Senior Research Background

Predictive Oncology Inc. (NASDAQ: POAI) Signs LOI for Acquisition of Leading Biomedical Analytics Company, Novel Drug-Discovery Platform

Predictive Oncology Inc.’s (NASDAQ: POAI) Key Focus Areas of Precision Medicine, AI Listed as Top Industry Investment Trends

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search